Scientific studies and patient testimonials have firmly demonstrated that atopic dermatitis (AD) is much more than a skin disease, with impacts that can affect virtually every aspect of life. In addition to these AD-specific impacts…
Published On: Jun 16, 2015
Last Updated On: Jul 15, 2021
Researchers at the Buck Institute for Research on Aging and the University of California, Berkeley have identified a serotonin receptor, HTR7, as a key mediator of eczema and other forms of itch.
Eczema is a debilitating condition that affects up to 10 percent of the worldwide population. Its symptoms include intense itch sensations, dry flaky skin, and a flaming red rash. Eczema can erode quality of life as dramatically as chronic pain does, and treatments to manage eczema are often not effective. But now, the Buck/Berkeley team has identified a new gene that may accelerate development of chronic itch therapies.
The work involved a collaboration between UC Berkeley neuroscientist Diana Bautista, Ph.D., who runs a lab focused on the molecular basis of the sensations of itch, touch and pain, and Buck associate professor Rachel Brem, Ph.D., a geneticist who studies how and why traits differ between individuals.
Bautista, Brem, and collaborators sought out genes whose expression was correlated with itch behavior across genetically distinct mouse strains. The serotonin receptor, HTR7, caught the scientists’ attention because the itchiest mice expressed the most HTR7 in the neurons that innervate the skin, and because abnormal serotonin signaling has long been linked to a variety of human chronic itch disorders, including eczema.
A battery of follow-up experiments then validated the role of HTR7 in chronic itch. In a mouse model of eczema, loss of the HTR7 gene in mice led to significantly less scratching and less severe skin lesions.
“We are really excited about these results. The dramatic decrease in itching suggests that HTR7 may represent a new drug target for chronic itch,” said Bautista, who is an Associate Professor in the Department of Molecular and Cell Biology and a member of the Helen Wills Neuroscience Institute at UC Berkeley.
Brem says that, in addition to eczema, altered serotonin signaling in the skin is found in other forms of itch, including psoriasis and allergic itch. Therefore, the new findings hold promise for treatment of many itch disorders.
In humans, itching and scratching can be side effects of taking antidepressants, which can elevate levels of serotonin in the skin. In the Buck/UC Berkeley study, this side effect was observed in mice, too—the drug Zoloft caused intense scratching, which vanished when the HTR7 gene was removed. Given that in humans HTR7 is also expressed in the neurons in the skin, this new gene may well be responsible for itch in human patients taking antidepressants.
“An estimated 10 to 20 percent of the population will suffer from chronic itch at some point in their lifetime,” said Brem. “In addition to eczema, chronic itch can stem from systemic conditions including kidney failure, cirrhosis and some cancers. Understanding the molecular basis of chronic itch is of significant clinical interest, and now there is a new target available to explore.”